Press Releases

NEW YORK --(BUSINESS WIRE)--Jan. 20, 2023-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on January 16, 2023 , the company granted (i) non-statutory stock options to purchase an

New Target Added to Ongoing Collaboration with Bristol Myers Squibb Unveils LRRK2 Inhibitor Program Targeting Neurodegenerative Diseases New Collaboration and Software Agreement with Otsuka Pharmaceutical Co., Ltd. NEW YORK --(BUSINESS WIRE)--Jan. 9, 2023-- Schrödinger , Inc.
Back To Top